Giastas Petros, Neu Margarete, Rowland Paul, Stratikos Efstratios
National Center for Scientific Research Demokritos, Agia Paraskevi, Athens 15310, Greece.
Medicinal Science and Technology, GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, U.K.
ACS Med Chem Lett. 2019 Feb 13;10(5):708-713. doi: 10.1021/acsmedchemlett.9b00002. eCollection 2019 May 9.
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that helps generate peptides presented by Major Histocompatibility Complex Class I (MHC class I) molecules and is an emerging target for immunotherapy applications. Despite almost two decades of research on ERAP1, lack of high-resolution crystal structures has hampered drug-development efforts. By optimizing the protein construct, we obtained a high-resolution (1.60 Å) crystal structure of the closed-conformation of ERAP1 with a potent phosphinic pseudopeptide inhibitor bound in its active site. The structure provides key insight on the mechanism of inhibition as well as selectivity toward homologous enzymes and allows detailed mapping of the internal cavity of the enzyme that accommodates peptide-substrates. Bis-tris propane and malic acid molecules, found bound in pockets in the internal cavity, reveal potential druggable secondary binding sites. The ability to obtain high-resolution crystal structures of ERAP1 removes a major bottleneck in the development of compounds that regulate its activity and will greatly accelerate drug-discovery efforts.
内质网氨肽酶1(ERAP1)是一种细胞内酶,有助于生成由主要组织相容性复合体I类(MHC I类)分子呈递的肽,并且是免疫治疗应用中一个新兴的靶点。尽管对ERAP1进行了近二十年的研究,但缺乏高分辨率晶体结构阻碍了药物开发工作。通过优化蛋白质构建体,我们获得了ERAP1封闭构象的高分辨率(1.60 Å)晶体结构,其活性位点结合了一种有效的次膦酸假肽抑制剂。该结构为抑制机制以及对同源酶的选择性提供了关键见解,并允许对容纳肽底物的酶内腔进行详细测绘。在内腔口袋中发现的双三羟甲基丙烷和苹果酸分子揭示了潜在的可成药二级结合位点。获得ERAP1高分辨率晶体结构的能力消除了调节其活性的化合物开发中的一个主要瓶颈,并将大大加速药物发现工作。